EPISODE · Dec 4, 2020 · 23 MIN
With a New Identity, Travere Thearpeutics Seeks to Find Its True Path
from RARECast
The rare disease drug developer Retrophin has been through a number of changes in recent years including a new CEO, a late-stage failure of a key program, and the resolution of dueling lawsuits between it and its former CEO and convicted fraudster Martin Shkreli. Now with data from its lead experimental therapy sparsentan expected next year in two different rare kidney diseases, the company has changed its name to Travere Therapeutics. We spoke to Eric Dube, CEO of Travere, about the company’s new identity, its experimental therapy sparsentan, and the rare kidney diseases it is being developed to treat.
Embed this episode
What this episode covers
Eric Dube, CEO of Travere Therapeutics, discusses the company’s new identity, its experimental therapy sparsentan, and the rare kidney diseases it is being developed to treat.
NOW PLAYING
With a New Identity, Travere Thearpeutics Seeks to Find Its True Path
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.